273.97
4.53 (1.68%)
4.53 (1.68%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Biogen Inc | BIIB | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 4.53 | 1.68% | 273.97 | 15:23:39 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 271.79 | 271.00 | 277.025 | 269.44 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 273.97 | 274.14 | 0.17 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 14,214 | 592,372 | $ 274.30 | $ 162,490,323 | 1,309,771 | 223.25 - 374.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:23:49 | 6 | $ 274.05 | USD |
Biogen Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 42.16B | 153.88M | 152.99M | $ 14.38B | $ 5.03B | 31.46 | 8.90 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Biogen News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 276.75 | 282.43 | 267.665 | 271.18 | 1,001,124 | -2.78 | -1.0% |
| 1 Month | 248.48 | 282.60 | 238.40 | 259.71 | 1,170,764 | 25.49 | 10.26% |
| 3 Months | 253.64 | 363.92 | 223.25 | 267.83 | 1,741,194 | 20.33 | 8.02% |
| 6 Months | 282.68 | 363.92 | 223.25 | 272.40 | 1,401,803 | -8.71 | -3.08% |
| 1 Year | 278.14 | 374.99 | 223.25 | 288.02 | 1,630,473 | -4.17 | -1.5% |
| 3 Years | 358.00 | 388.67 | 215.775 | 283.37 | 1,660,561 | -84.03 | -23.47% |
| 5 Years | 269.46 | 388.67 | 215.775 | 284.07 | 1,600,180 | 4.51 | 1.67% |
Biogen Description
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. |
